Lundbeck breathes life into stranded molecule to treat new diseases
Drug candidate LU AG06466, which failed as a treatment for Tourette's, is the center of attention in two new phase I trials Lundbeck has launched this summer.
Lundbeck means business in picking drug candidate LU AG06466 back up again. The Danish pharmaceutical company is testing the drug in three phase I trials. In March 2020, it failed as a treatment for Tourette's syndrome in a phase II trial.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck: acquisitions must be well considered
For subscribers
Lundbeck closes RNA deal worth USD 109m with US biotech firm
For subscribers
Takeda surpasses analyst forecasts in Q1
For subscribers
.jpg&w=384&q=75)
